M&A / Deals EverSea Medicines to acquire Hasten Biopharmaceuticals Pharmaceutical Business ReviewThe acquisition aims to enhance Everest Medicines' presence and commercial capabilities across key regional markets.M&A / DealsRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Pharmaceutical Business Review The acquisition aims to enhance Everest Medicines’ presence and commercial capabilities across key regional markets. M&A / DealsRead full story Post navigation Previous: Jeito Capital secures over $1.2bn for new biopharma investmentsNext: 23andMe study explains variable results with obesity drugs Related Stories M&A / Deals Assertio accepts new buyout bid; AI biotech Isomorphic banks $2B pharminent May 13, 2026 M&A / Deals BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal pharminent May 12, 2026 M&A / Deals Cellular Intelligence scoops up Novo’s Parkinson’s therapy pharminent May 12, 2026
